Chiesi and Protalix Achieve Milestone in Fabry Disease Treatment with Pegunigalsidase Alfa Chiesi Global Rare Diseases and Protalix BioTherapeutics celebrate the European Medicines Agency's validation for a new dosing regimen of pegunigalsidase alfa.

Chiesi and Protalix Achieve Milestone in Fabry Disease Treatment with Pegunigalsidase Alfa #Italy #Protalix_BioTherapeutics #Parma #Chiesi_Global_Rare #Pegunigalsidase_Alfa